Key result
Trastuzumab emtansine administered for approximately 1 year after anthracycline-based chemotherapy resulted in 0 prespecified cardiac events, demonstrating feasibility and cardiac safety in patients with HER2-positive early-stage breast cancer.
Why the study?
Is trastuzumab emtansine (T-DM1) feasible and safe from a cardiac perspective when given after anthracycline-based chemotherapy in patients with HER2-positive early-stage breast cancer?
Is trastuzumab emtansine (T-DM1) feasible and safe from a cardiac perspective when given after anthracycline-based chemotherapy in patients with HER2-positive early-stage breast cancer?
Trastuzumab emtansine (T-DM1) administered for approximately 1 year after anthracycline-based chemotherapy is feasible and demonstrates a favorable cardiac safety profile in patients with HER2-positive early-stage breast cancer.
No takes yet. Share an insight, caveat, or question.
Should not yet change practice; hypothesis-generating for cardiac safety of sequential T-DM1 after anthracyclines.
Krop et al. (2015) studied HER2-positive early-stage breast cancer (n=153). Trastuzumab emtansine (T-DM1) was evaluated on Rate of prespecified cardiac events (death from cardiac cause or severe CHF with LVEF decline ≥10 percentage points to <50%) within the first 12 weeks of T-DM1 treatment (95% CI 0-2.45). Trastuzumab emtansine administered for approximately 1 year after anthracycline-based chemotherapy resulted in 0 prespecified cardiac events, demonstrating feasibility and cardiac safety in patients with HER2-positive early-stage breast cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: